Risperdal Consta (Johnson & Johnson): Global Drug Overview & Outlook 2017/2018-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Risperdal Consta" report has been added to ResearchAndMarkets.com's offering.

Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson & Johnson's oral drug Risperdal.

Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson & Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson & Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Risperdal Consta: Bipolar disorder
  4. Risperdal Consta: Schizophrenia

List of Figures
Figure 1: Risperdal Consta for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 3: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 4: Risperdal Consta for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 6: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Risperdal Consta bipolar disorder indication approvals
Table 2: Risperdal Consta drug profile
Table 3: Risperdal Consta pivotal trial data in bipolar disorder
Table 4: Adverse reactions in =5% of Risperdal Consta-treated adult patients with bipolar disorder
Table 5: Risperdal Consta drug profile
Table 6: Risperdal Consta pivotal trial data in schizophrenia
Table 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/7st2hq/risperdal_consta?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs